Skip to main content
. Author manuscript; available in PMC: 2022 May 13.
Published in final edited form as: N Engl J Med. 2008 Nov 27;359(22):2313–2323. doi: 10.1056/NEJMoa0802885

Figure 1. Gene-Expression Predictors of Survival among Patients with Diffuse Large-B-Cell Lymphoma Treated with R-CHOP.

Figure 1.

Kaplan–Meier estimates of progression-free and overall survival are shown. Panel A shows that patients with germinal-center B-cell–like diffuse large-B-cell lymphoma had a higher probability of progression-free survival (left) and overall survival (right) than patients with activated B-cell–like diffuse large-B-cell lymphoma. Panel B shows a gene-expression–based predictor of survival among patients with diffuse large-B-cell lymphoma treated with R-CHOP. Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) are based on a multivariate model derived from the germinal-center B-cell, stromal-1, and stromal-2 gene-expression signatures. Survival-predictor scores derived from this model were used to rank the cases of lymphoma, which were then divided into quartile groups as indicated. R-CHOP denotes rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone.